Then, the expression of the KRAS4A and KRAS4B cmRNA isoforms, together with KRAS mutational status and PD-L1 tumor expression by immunohistochemistry (IHC) were evaluated for their association with PD-L1 cmRNA level. Here, KRAS is linked to neoplasm.